BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16476276)

  • 1. [Eccrine squamous syringometaplasia from chemotherapy extravasation].
    Bordel MT; Miranda A
    Actas Dermosifiliogr; 2005 Sep; 96(7):462-4. PubMed ID: 16476276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy-induced eccrine squamous syringometaplasia in an infant.
    Bittar PG; Casady M; Selim MA; Prose NS
    Pediatr Dermatol; 2018 Jan; 35(1):e84-e85. PubMed ID: 29231256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib-induced eccrine squamous syringometaplasia.
    Van de Voorde K; De Raeve H; Van Regenmortel N; Lambert J
    J Am Acad Dermatol; 2006 Aug; 55(2 Suppl):S58-9. PubMed ID: 16843129
    [No Abstract]   [Full Text] [Related]  

  • 4. Eccrine squamous syringometaplasia secondary to cutaneous extravasation of docetaxel: report of three cases.
    Gallo E; Llamas-Velasco M; Navarro R; Fraga J; García-Diez A
    J Cutan Pathol; 2013 Mar; 40(3):326-9. PubMed ID: 23170995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-induced eccrine squamous syringometaplasia. A distinctive eruption in patients receiving hematopoietic progenitor cells.
    Valks R; Fraga J; Porras-Luque J; Figuera A; Garcia-Diéz A; Fernändez-Herrera J
    Arch Dermatol; 1997 Jul; 133(7):873-8. PubMed ID: 9236526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vemurafenib-induced eccrine squamous syringometaplasia.
    Lescoat A; Droitcourt C; Stock N; Le Gall F; Dupuy A
    Dermatology; 2013; 226(4):362-4. PubMed ID: 23860306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eccrine squamous syringometaplasia associated with vemurafenib therapy.
    Story SG; Beschloss JK; Dolan CK; Thomas BC
    J Am Acad Dermatol; 2012 Nov; 67(5):e208-10. PubMed ID: 23062917
    [No Abstract]   [Full Text] [Related]  

  • 8. Chemotherapy-related bilateral dermatitis associated with eccrine squamous syringometaplasia: reappraisal of epidemiological, clinical, and pathological features.
    Martorell-Calatayud A; Sanmartín O; Botella-Estrada R; Balmer NN; Serra-Guillén C; Gomez-Moyano E; Traves-Zapata V; Requena C; Nagore E; Llombart-Cussac B; Guillen-Barona C
    J Am Acad Dermatol; 2011 Jun; 64(6):1092-103. PubMed ID: 21489654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eccrine squamous syringometaplasia in an allogenic stem cell transplant patient undergoing chemotherapy.
    Nethers K; Messina J; Seminario-Vidal L
    Dermatol Online J; 2017 Sep; 23(9):. PubMed ID: 29469718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine-induced eccrine squamous syringometaplasia.
    Molina-Ruiz AM; Molina-Ruiz RM; Zulueta T; Barabash R; Requena L
    Am J Dermatopathol; 2012 Jun; 34(4):434-7. PubMed ID: 22257902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen-induced eccrine squamous syringometaplasia.
    Teoh DC; Aw DC; Jaffar H; Ling W; Yong WP; Lee YS; Choo SN; Tan KB
    J Cutan Pathol; 2012 May; 39(5):554-7. PubMed ID: 22390276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Syringometaplasia: mucinous and squamous variants.
    King DT; Barr RJ
    J Cutan Pathol; 1979 Aug; 6(4):284-91. PubMed ID: 500875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eccrine squamous syringometaplasia associated with dabrafenib therapy.
    Liuti F; Martín PA; Montenegro Damaso T; Abreu DR; Santana JH
    J Am Acad Dermatol; 2013 Nov; 69(5):e273-e274. PubMed ID: 24124864
    [No Abstract]   [Full Text] [Related]  

  • 14. Eccrine squamous syringometaplasia and syringomatous hyperplasia in association with linear scleroderma.
    Sakai H; Satoh K; Manabe A; Nakane H; Ishida-Yamamoto A; Iizuka H
    Dermatology; 2002; 204(2):136-8. PubMed ID: 11937740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Syringosquamous metaplasia. A distinctive eruption in patients receiving chemotherapy.
    Bhawan J; Malhotra R
    Am J Dermatopathol; 1990 Feb; 12(1):1-6. PubMed ID: 2316809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of bleomycin-induced acral erythema (AE) with eccrine squamous syringometaplasia (ESS) and summary of reports of AE with ESS in the literature.
    Tsuboi H; Yonemoto K; Katsuoka K
    J Dermatol; 2005 Nov; 32(11):921-5. PubMed ID: 16361756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eccrine squamous syringometaplasia in sites of radiation recall secondary to vemurafenib therapy for BRAF-mutated carcinoma.
    Moioli EK; Ligtenberg KG; Kenkare S; Shea CR; Soltani K
    J Dermatol; 2016 Oct; 43(10):1233-1234. PubMed ID: 27094584
    [No Abstract]   [Full Text] [Related]  

  • 18. Leukemia cutis and eccrine squamous syringometaplasia.
    Bouceiro-Mendes R; Antunes-Duarte S; Aguado-Lobo M; Espinosa-Lara P; Soares-de-Almeida L; Filipe P
    Dermatol Online J; 2021 Jun; 27(6):. PubMed ID: 34387058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eccrine squamous syringometaplasia in intertriginous areas.
    Valks R; Buezo GF; Daudén E; Fraga J; García-Díez A
    Br J Dermatol; 1996 May; 134(5):984-6. PubMed ID: 8736357
    [No Abstract]   [Full Text] [Related]  

  • 20. [Eccrine squamous syringometaplasia and cytomegalovirus infection].
    Baysse L; Boralevi F; Lepreux S; Boyer A; Morel C; Léauté-Labrèze C; Taïeb A
    Rev Med Interne; 2003 Jun; 24(6):394-8. PubMed ID: 12814829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.